MK-677 (ibutamoren) is an orally active small molecule, not a peptide and not a SARM. With no injectable route and no dose in Peptigrity's sources, this page does the one honest calculation — amounts per container from the label — and says plainly that no independent test on file yet confirms any label. The compound is covered in the MK-677 guide.
A 10 mg MK-677 container — the size in stock on its price page on 21 Sep 2026 — holds 10 mg of compound on its label, so each milligram measured out of it is 1 ÷ 10 = 10% of the container and the number of amounts it holds is 10 mg ÷ the amount you enter. MK-677 had 0 independent lab tests on Peptigrity as of 21 September 2026, so nothing on this site confirms that any container holds its label.
MK-677 is orally active and has no injectable route in Peptigrity's sources, so this calculator prints no syringe units. There are no cost tiles: when the price feed was read on 21 Sep 2026 it held one comparable in-stock offer, which is one shop's price rather than a market figure.
MK-677 has 0 independent lab tests on file at Peptigrity. There is therefore no purity figure to show for it, and none is implied by anything on this page: a calculator converts the mass on a label, it does not confirm it.
MK-677 (INN ibutamoren; codes MK-0677 and L-163,191) is an orally active, long-acting agonist of the ghrelin receptor, GHSR-1a, developed by Merck & Co. as a growth hormone secretagogue. It is frequently mislabelled as both a peptide and a SARM; it is neither. The table below is what the compound page states, as last updated in August 2026.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A non-peptide spiroindoline small molecule; a ghrelin-receptor agonist and GH secretagogue | Chemical identity |
| A peptide, a SARM or a steroid? | None of the three — it does not bind androgen receptors | Pharmacology |
| Which route? | Orally active; orally bioavailable (~60–70%) | Stated on the compound page |
| Human evidence? | Raises GH and IGF-1 across controlled studies; a 2-year trial in older adults increased fat-free mass without demonstrated functional benefit | Human RCTs on surrogate endpoints; not approved |
| Safety signals? | Increased appetite, water retention, reduced insulin sensitivity; a Phase IIb hip-fracture trial was terminated early for a congestive-heart-failure signal | Human RCT |
| A dose on Peptigrity? | “No. It is not approved for human use and Peptigrity is an independent review platform, not a medical authority.” | None — declined |
| Independent lab tests? | 0 on file (fact sheet, as of 21 September 2026) | None |
The compound-specific caveat is the empty test record. The compound page calls MK-677 a cheap-to-counterfeit oral compound with real underdosing and mislabelling risk, and names independent HPLC and mass spectrometry (expected molecular weight 528.67) as the objective checks. Neither has been run on any MK-677 sample on file here yet, so every container figure on this page rests on a label that nobody has measured. How the three classes differ: peptides vs SARMs vs steroids.
No dose table, because MK-677 is not approved for any indication and the compound page declines the dose question. No syringe arithmetic and no diluent step, because the route the compound page names is oral and no injectable route appears in Peptigrity's sources. The compound page describes a once-daily oral profile as MK-677's point of difference from injectable secretagogues such as ipamorelin; it attaches no milligram figure to it, and this page does not supply one.
Amounts per container = label mg ÷ your amount. Each milligram is 10% of a 10 mg container and 3.33% of a 30 mg container; the container sizes in the calculator are the two on the price page. The calculator shows no cost figures: on 21 Sep 2026 the price page held one comparable in-stock offer and one out-of-stock offer, with most known listings sold only as multi-vial kits, and the compound page's own fact sheet records no price feed for MK-677 (fewer than 3 comparable in-stock listings). A single offer is not a market price. The listings are on the MK-677 price page.
Because MK-677 has no measured-versus-labelled results on file, this page cannot say whether containers tend to run over or under their label. What it can say is how to change that: an independent test with an identity result. The testing planner works out which test answers which question, and reading lab test results explains what a certificate should show.
Per the compound page, MK-677 is an investigational compound not approved by the FDA or any regulator for any indication, and it is not available by prescription. Its salt, ibutamoren mesylate, is on the FDA's Category 2 list of bulk drug substances that “may present significant safety risks” in compounding, flagged for both 503A pharmacy compounding and 503B outsourcing — one of five substances on the active Category 2 list, with GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10, as of August 2026. In sport, the WADA 2026 Prohibited List names “ibutamoren (MK-677)” under S2.2.4, growth hormone secretagogues, prohibited at all times (as of August 2026).
Country rules: regulatory status by country. The growth-hormone compounds MK-677 is grouped with: growth hormone peptides.
Peptigrity does not state one. MK-677 is not approved by the FDA or any regulator for any indication, and the compound page declines the dose question: Peptigrity is an independent review platform, not a medical authority. This calculator divides a container by an amount you enter; it has no amount to suggest.
Neither. It is a non-peptide spiroindoline small molecule that acts on the ghrelin receptor (GHSR-1a) as a growth hormone secretagogue. It does not bind androgen receptors, so it is not a SARM.
MK-677 is orally active - the compound page gives an oral bioavailability of about 60-70% - and no injectable route appears in Peptigrity's sources, so there is nothing to measure on a syringe.
Not yet. MK-677 had 0 independent lab tests on file as of 21 September 2026, so there is no purity figure and no measured-versus-labelled result for it. The compound page names HPLC and mass spectrometry against an expected molecular weight of 528.67 as the objective checks.
Yes. The WADA 2026 Prohibited List names ibutamoren (MK-677) under S2.2.4, growth hormone secretagogues, prohibited at all times (as of August 2026).